Home › Pfizer's RAPAMUNE (sirolimus) Becomes First FDA-Approved Treatment For Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease
 

Keywords :   


Pfizer's RAPAMUNE (sirolimus) Becomes First FDA-Approved Treatment For Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease

2015-06-03 06:19:12| drugdiscoveryonline Home Page

Pfizer Inc. announced recently that the U.S. Food and Drug Administration (FDA) has approved RAPAMUNE (sirolimus) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive disease that affects the lungs, kidneys and the lymphatic system

Tags: treatment disease rare progressive

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.05Melting Massage Bar Patented by Johnson & Johnson
03.05How the computer games industry is embracing AI
03.05Apple sees biggest fall in sales for a year
02.05Turkey halts trade with Israel over Gaza 'tragedy'
02.05Loop Industries and Ester Ltd. Announce Joint Venture
02.05The Oldham Group names Hunter Collins account manager
02.05NCBAs Sigrid Johannes promoted to Senior Director of Government Affairs
02.05University helps neighboring ranchers oust redcedars
More »